Capricor Therapeutics

Описание к видео Capricor Therapeutics

Linda Marban, Ph.D., CEO
(NASDAQ: CAPR)
Headquarters: Los Angeles, CA

Capricor Therapeutics is a clinical stage biotechnology company focused on the treatment of fibrotic and inflammatory diseases. A developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − heart disease. Capricor Therapeutics’ lead product candidates will target the prevention and treatment of heart disease, both as a result of injury to the heart such as a heart attack or heart failure, and also orphan disease cardiomyopathies, such as Duchenne Muscular Dystrophy, where Capricor’s lead product has been shown pre-clinically to improve heart function and exercise capacity. The Company’s second class of products are naturietic peptides to treat advanced heart failure, the first of which is Cenderitide. Capricor’s deep bench in cardiology gives it a unique ability to develop a diverse pipeline of products to treat heart disease.
www.capricor.com

Комментарии

Информация по комментариям в разработке